Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

por Zinzani, Pier Luigi, Santoro, Armando, Gritti, Giuseppe, Brice, Pauline, Barr, Paul M., Kuruvilla, John, Cunningham, David, Kline, Justin, Johnson, Nathalie A., Mehta-Shah, Neha, Lisano, Julie, Wen, Rachael, Akyol, Alev, Moskowitz, Alison J.
Publicado 2023

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

por Ansell, Stephen M., Bröckelmann, Paul J., von Keudell, Gottfried, Lee, Hun Ju, Santoro, Armando, Zinzani, Pier Luigi, Collins, Graham P., Cohen, Jonathon B., de Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trněný, Marek, Provencio, Mariano, Jäger, Ulrich, Willenbacher, Wolfgang, Wen, Rachael, Akyol, Alev, Mikita-Geoffroy, Joanna, Shipp, Margaret A., Engert, Andreas, Armand, Philippe
Publicado 2023